Compare Gap Inc (GAP) vs TG Therapeutics Inc (TGTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Gap Inc vs TG Therapeutics Inc — how do they compare? Gap Inc trades at $20.3 (market cap $7.55B), while TG Therapeutics Inc trades at $50.35 (market cap $7.64B). The key difference: Gap Inc and TG Therapeutics Inc are close in size by market cap, and Gap Inc pays a 3.34% dividend while TG Therapeutics Inc pays none. Which is the better fit depends on your goals.
| GAP | TGTX | |
|---|---|---|
Market Cap | $7.55B | $7.64B |
Sector | Consumer Cyclical | Health |
52-Week High | $29.13 | $59.06 |
52-Week Low | $18.35 | $26.94 |
Enterprise Value | $10.63B | $7.84B |
Dividend Yield | 3.34% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Gap Inc. (GAP) trades at $21.51, up 5.08% today, showing strong momentum amid a bullish technical outlook. The stock presents compelling value with a P/E of 8.32 and P/S of 0.52, well below industry averages. Recent earnings have mostly beaten expectations, with Q1 2026 EPS of $0.38 exceeding estimates. Revenue growth has stabilized at $15.1B for 2025, while net income margin improved to 5.59%. The company maintains solid cash flow generation with $464M net cash flow in 2025.
Gap offers attractive valuation upside with a consensus price target of $26.09 (21% potential). However, risks include ongoing investigations by Pomerantz Law Firm and competitive pressures in retail. The turnaround story appears credible with nine consecutive positive comps, but execution risks remain. Current technical indicators suggest the stock is approaching overbought territory with RSI above 70.
TGTX trades at $50.26, up 2.24% in the last session, with a bearish technical signal from moving averages despite neutral oscillators. Recent Q2 2026 earnings missed estimates at $0.05 per share versus $0.3057 expected, though revenue surged to $240 million, driven by strong BRIUMVI sales growth of 64% year-over-year. The company raised 2026 revenue guidance to $950 million, reflecting robust demand for its multiple sclerosis treatment.
The outlook is mixed: strong revenue growth and a high analyst buy consensus (84.62%) support upside to the $63.75 price target, but earnings misses, a high EV/EBITDA of 56.26, and a shareholder investigation into fiduciary breaches pose risks. Investors should weigh the growth potential against execution and regulatory uncertainties.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Gap Inc
Gap retails apparel, accessories, and personal-care products under the Gap, Old Navy, Banana Republic, and Athleta brands. Old Navy generates more than half of Gap's sales. The firm also operates e-commerce sites, outlet stores, and specialty stores under various Gap names. Gap operates nearly 3,000 stores in North America, Europe, and Asia and franchises about 600 stores in Asia, Europe, Latin America, and other regions. Gap was founded in 1969 and is based in San Francisco.
Read more on GAP →About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →
